---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-026771"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2026-08-10T20:07:12+00:00"
generated_at: "2026-08-10T20:08:17.801978+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CervoMed Q2 net loss $6.6M; neflamapimod data supports Phase 3 DLB plan

## Summary
- Net loss $6.6M vs $6.3M YoY; cash $24.9M at June 30, 2026, runway to Q3 2027.
- Grant revenue zero vs $1.8M; R&D $4.3M vs $5.1M; G&A $2.4M vs $3.3M.
- AAIC data: CDR-SB improvement 0.70 (p=0.054) in pure DLB; basal forebrain atrophy slowed (p=0.028).
- Neflamapimod awarded UK ILAP Innovation Passport; company pursuing partnership for Phase 3 DLB trial.
- Raised ~$20.5M gross in June equity financings; ended RAS enrollment, completed nfvPPA enrollment.

## SEC filing metadata
- accession: 0001437749-26-026771
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2026-08-10T20:07:12+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774926026771/0001437749-26-026771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774926026771/crvo20260810_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-026771
- JSON: https://secwatch.observer/filing/0001437749-26-026771.json
- Plain text: https://secwatch.observer/filing/0001437749-26-026771.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.